Evolocumab vs. Ezetimibe in Addition to Statins for Secondary Prevention of Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes and Hypercholesterolemia.

被引：0
|
作者：
Azuri, Joseph [1 ]
Hammerman, Ariel [2 ]
Arbel, Ronen [3 ]
机构：
[1] Tel Aviv Univ, Family Med, Sackler Fac Med, Tel Aviv, Israel
[2] Clalit Hlth Serv, Med, Tel Aviv, Israel
[3] Sapir Coll, Med, Sderot, Israel
来源：
CIRCULATION | 2018年 / 138卷
关键词：
Diabetes (Type II); Endpoint events; LDL; PCSK9; Efficacy;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A12027
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Tirzepatide versus Semaglutide for Secondary Prevention of Major Adverse Cardiovascular Events in Patients Over the Age of 65 With Type 2 Diabetes Mellitus-Value per Money Analysis
    Arbel, Ronen
    Hammerman, Ariel
    Aboalhasan, Enis
    Sluckis, Ben
    Azuri, Joseph
    CIRCULATION, 2022, 146
  • [22] No difference in Major Adverse Cardiovascular Events (MACE plus ) with Basal Insulin peglispro (BIL) vs comparator insulins in patients with type 1 or type 2 diabetes
    Bergenstal, R. M.
    Lincoff, A. M.
    Rodriguez, A.
    Chen, L.
    Qu, Y.
    Prince, M. J.
    Hoogwerf, B. J.
    DIABETOLOGIA, 2015, 58 : S65 - S66
  • [23] Association of the cumulative triglyceride-glucose index with major adverse cardiovascular events in patients with type 2 diabetes
    Shi Tai
    Liyao Fu
    Ningjie Zhang
    Rukai Yang
    Yuying Zhou
    Zhenhua Xing
    Yongjun Wang
    Shenghua Zhou
    Cardiovascular Diabetology, 21
  • [24] Association of the cumulative triglyceride-glucose index with major adverse cardiovascular events in patients with type 2 diabetes
    Tai, Shi
    Fu, Liyao
    Zhang, Ningjie
    Yang, Rukai
    Zhou, Yuying
    Xing, Zhenhua
    Wang, Yongjun
    Zhou, Shenghua
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [25] Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney
    Dario Giugliano
    Luca De Nicola
    Maria Ida Maiorino
    Giuseppe Bellastella
    Carlo Garofalo
    Paolo Chiodini
    Antonio Ceriello
    Katherine Esposito
    Cardiovascular Diabetology, 19
  • [26] Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney
    Giugliano, Dario
    De Nicola, Luca
    Maiorino, Maria Ida
    Bellastella, Giuseppe
    Garofalo, Carlo
    Chiodini, Paolo
    Ceriello, Antonio
    Esposito, Katherine
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
  • [27] Statins and beyond: Concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes
    Standl, Eberhard
    DIABETES & VASCULAR DISEASE RESEARCH, 2013, 10 (02): : 99 - 114
  • [28] Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus
    Riche, Daniel M.
    McClendon, Katie S.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2007, 64 (15) : 1603 - 1610
  • [29] Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins
    Bays, Harold E.
    Baum, Seth J.
    Brinton, Eliot A.
    Plutzky, Jorge
    Hanselman, Jeffrey C.
    Teng, Rujun
    Ballantyne, Christie M.
    AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 8
  • [30] Chronic Kidney Disease, Type 2 Diabetes, and the Risk of Major Cardiovascular Events in Coronary Artery Disease vs. Peripheral Artery Disease Patients
    Sprenger, Lukas
    Maechler, Maximilian
    Vonbank, Alexander
    Larcher, Barbara
    Mader, Arthur
    Leiherer, Andreas
    Muendlein, Axel
    Drexel, Heinz
    Saely, Christoph H.
    DIABETES, 2022, 71
12345